Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor)

British Journal of Pharmacology

Volumn 173, Issue 3, 2016, Pages 459-470

  Matthes, Elizabeth ^a,b   Goepp, Julie ^a,b   Carlile, Graeme W ^b   Luo, Yishan ^a,b   Dejgaard, Kurt ^b   Billet, Arnaud ^a,b   Robert, Renaud ^a,b   Thomas, David Y ^b   Hanrahan, John W ^a,b,c  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; GENISTEIN; IVACAFTOR; IVACAFTOR PLUS LUMACAFTOR; LUMACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; BRONCHUS MUCOSA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; EPITHELIUM CELL; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM EXPOSURE; MONOLAYER CULTURE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY EPITHELIUM; SHORT CIRCUIT CURRENT; BRONCHUS; CELL CULTURE; CELL LINE; CYTOLOGY; DRUG EFFECTS; DRUG INTERACTION; GENETICS; METABOLISM; MUTATION;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; BRONCHI; CELL LINE; CELLS, CULTURED; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG INTERACTIONS; EPITHELIAL CELLS; HUMANS; MUTATION; QUINOLONES;

EID: 84956576168     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13365     Document Type: Article

References (33)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al., (2013). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
2. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, et al., (1991). Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253: 202-205.
3. Bear CE, Li C, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M, et al., (1992). Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68: 809-818.
4. - airway epithelial monolayers. J Physiol 569: 601-615.
5. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al., (2014). A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2: 527-538.
6. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, et al., (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827-834.
7. Cholon DM, Quinney NL, Fulcher ML, Esther CR Jr, Das J, Dokholyan NV, et al., (2014). Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Sci Transl Med 6: 246ra296.
8. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, et al., (1991). Altered chloride ion channel kinetics associated with the DF508 cystic fibrosis mutation. Nature 354: 526-528.
9. Deeks ED, (2013). Ivacaftor: a review of its use in patients with cystic fibrosis. Drugs 73: 1595-1604.
10. Fogh-Andersen N, Altura BM, Altura BT, Siggaard-Andersen O, (1995). Composition of interstitial fluid. Clin Chem 41: 1522-1525.
11. Fulcher ML, Gabriel S, Burns KA, Yankaskas JR, Randell SH, (2005). Well-differentiated human airway epithelial cell cultures. Methods Mol Med. 107: 183-206.
12. Hanrahan JW, Sampson HM, Thomas DY, (2013). Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol Sci 34: 119-125.
13. Kartner N, Hanrahan JW, Jensen TJ, Naismith AL, Sun S, Ackerley CA, et al., (1991). Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. Cell 64: 681-691.
14. Kell DB, Oliver SG, (2014). How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol 5: 231.
15. Kunzelmann K, Schwiebert EM, Zeitlin PL, Kuo WL, Stanton BA, Gruenert DC, (1993). An immortalized cystic fibrosis tracheal epithelial cell line homozygous for the delta F508 CFTR mutation. Am J Respir Cell Mol Biol 8: 522-529.
16. Kwong TC, (1985). Free drug measurements: methodology and clinical significance. Clinica chimica acta; international journal of clinical chemistry 151: 193-216.
17. Lukacs GL, Chang X-B, Bear C, Kartner N, Mohamed A, Riordan JR, et al., (1993). The DF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem 268: 21592-21598.
18. Matthes E, Goepp J, Robert R, Dejgaard K, Carlile GW, Thomas DY, et al., (2014). Protein binding prevents inhibition of F508del-CFTR correction by clinically-relevant concentrations of Vx-770. Pediatr Pulmonol 49: 219-219.
19. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-D1106.
20. Randell SH, Boucher RC, (2006). Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 35: 20-28.
21. Raunio H, Hakkola J, Pelkonen O, (2005). Regulation of CYP3A genes in the human respiratory tract. Chem Biol Interact 151: 53-62.
22. Riordan JR, Rommens JM, Kerem B-S, Alon N, Rozmahel R, Grzelczak Z, et al., (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073.
23. Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, et al., (2007). Structural analogue of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 73: 478-489.
24. Rommens JM, Iannuzzi MC, Kerem B-S, Drumm ML, Melmer G, Dean M, et al., (1989). Identication of the cystic fibrosis gene: chromosome walking and jumping. Science 245: 1059-1065.
25. Schneider EK, Huang JX, Carbone V, Baker M, Azad MA, Cooper MA, et al., (2015). Drug-drug plasma protein binding interactions of ivacaftor. J Mol Recogn: JMR 28: 339-348.
26. Smith DA, Di L, Kerns EH, (2010). The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev. Drug Discov 9: 929-939.
27. U.S. Food and Drug Administration CfDEaR (2012). Ivacaftor NDA 202188,Clinical Inspection Summary, Access data FDA:203188Orif1s000.
28. van Goor F, Yu H, Burton B, Hoffman BJ, (2014). Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cystic Fibrosis: Official J Eur Cystic Fibrosis Soc 13: 29-36.
29. van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, et al., (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 108: 18843-18848.
30. van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al., (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 106: 18825-18830.
31. Veit G, Avramescu RG, Perdomo D, Phuan PW, Bagdany M, Apaja PM, et al., (2014). Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med 6: 246-297.
32. Wu X, Wakefield JK, Liu H, Xiao H, Kralovics R, Prchal JT, et al., (2000). Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther: J Am Soc Gene Ther 2: 47-55.
33. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr, et al., (2012). Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cystic Fibrosis: Official J Eur Cystic Fibrosis Soc 11: 237-245.